Učitavanje...
MEK inhibition and immune responses in advanced melanoma
phase II and III clinical trials demonstrated modest anti- tumor activity of Binimetinib (MEK162) - a potent allosteric inhibitor of MEK1 and MEK2- in patients with advanced NRAS mutant melanoma. The analysis of the NEMO study in NRAS mutated melanoma, has shown that pre-treatment with immunotherapy...
Spremljeno u:
| Izdano u: | Oncoimmunology |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5593717/ https://ncbi.nlm.nih.gov/pubmed/28919996 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1335843 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|